Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
about
Carcinoid tumorsExpression of somatostatin receptor type-2 (sst2A) in immature porcine Leydig cells and a possible role in the local control of testosterone secretionPET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literatureQuantitative and functional expression of somatostatin receptor subtypes in human thymocytesBiodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide.Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.Oxyntic endocrine cells of hypergastrinaemic patients. Differential response to antrectomy or octreotide.Pancreatic surgical complications--the case for prophylaxisInhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanismsSomatostatin analogs and radiopeptides in cancer therapy.Genome wide analysis reveals single nucleotide polymorphisms associated with fatness and putative novel copy number variants in three pig breeds.Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells.Treatment of hepatocellular carcinoma with octreotide: a randomised controlled studyUse of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours.Immunohistochemical localization of somatostatin receptors sst2A in human tumors.Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors.Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in IndiaSomatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumorsCardiac manifestations of gastrointestinal carcinoid tumor.Ileal neuroendocrine tumors and heart: not only valvular consequences.Identification of a functional 3',5'-cyclic adenosine monophosphate response element within the second promoter of the mouse somatostatin receptor type 2 gene.Novel gold nanoparticles coated with somatostatin as a potential delivery system for targeting somatostatin receptors.Synthesis and structure-activity relationship study of organometallic bioconjugates of the cyclic octapeptide octreotate.Carcinoid tumours.111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.Signal transduction of somatostatin in human B lymphoblasts.The biology and clinical relevance of somatostatin receptor scintigraphy in adrenal tumor managementInduction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.Somatostatin receptor subtype SSTR2 mediates the inhibition of high-voltage-activated calcium channels by somatostatin and its analogue SMS 201-995.Molecular pharmacology of somatostatin receptor subtypes.Somatostatin-induced control of cytosolic free calcium in pituitary tumour cells.Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours.Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours.In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous.Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours.Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors
P2860
Q24614827-38D20CC5-8062-4DD0-B86F-F05F56DFCFC3Q24806009-99C1E8E2-C716-4573-B039-FB4BAF6CB848Q26992201-EF962FDA-F3F2-4830-95E6-791FE8EACFDEQ28206900-225DAB29-7531-45F5-A53B-1CEE62296BE2Q30957907-B648C03E-C48F-45B6-9BD5-8A4994DB299DQ34117185-DF26B106-2697-48B7-B230-30EC935B4DC8Q34409167-1060F98F-5EC5-4745-A38C-259B02901FBCQ34409661-E0C3F95D-B8CD-4A22-A4E4-AFF8E080DAB8Q34552348-9564671B-19AF-456F-A463-2710D5655C3FQ34634036-722BEE37-DB73-46D5-8DE9-6E370377A679Q34972896-D66EC67E-0F1A-43A4-9B3B-52C6D9AC182FQ35041895-BDC1BE05-18F9-45CB-BE33-A499840131E6Q35046099-551DD774-3BC4-440F-8AE8-8AEF72F610B7Q35349653-4EB975F2-4F22-487E-80C4-D3B1E7005C37Q35351072-2A22CD54-1DB4-46B9-8515-47EB5899FA62Q35753168-DFBA90A8-3CC4-46FB-A3E9-271D6EC50A9EQ36008285-41E2E0D3-5BB1-4DDA-8B57-69A8E3BFD868Q36291710-25ED4D52-EA9C-4CED-87E4-61E26A7F7A13Q36936960-B99AA353-EA12-4D9D-850B-35A9542E1F07Q37363625-82E0F29B-B387-4247-BB3D-C54A164A2D20Q37374477-9A894871-1309-4F3D-9C74-10598875BB5CQ38120087-D8AA9D3F-61BF-429E-BECB-AD051531AB41Q38260542-F095EEC6-7104-42F8-8C56-E174DED3AC42Q38330243-48B46950-153B-445A-B642-4BA99B587FC4Q38782137-2B6988C8-4A0E-4E5E-86AD-15D5922679D7Q39064228-5FF90178-EA1D-4542-AF4A-1DA18AC5EAFAQ39271492-B3396702-6186-4818-ABB8-490EF800D0CDQ40397426-CAF81671-1F1B-45A2-A7FF-C9B3DD156B3DQ40696292-0B28BE5E-15CA-47D9-A8F4-63179E156226Q40834649-E5E565A4-F14F-4C38-A4C0-9500E85FBA54Q41136882-1622D9C0-0AAD-43A8-B8D3-901D4C8B1124Q41428116-87D1B50B-E947-46BC-B0D0-1729B5159222Q41592810-4A9E874E-8443-4822-BECC-AEF66DB2BD7AQ42484756-7EFBA78C-0BA7-4E39-9600-0A5DFD0D04B9Q44148184-18CA3B13-207A-4A3C-ADD4-3E87F4127C07Q50539676-59C47C29-5777-401F-B8DE-0070785227B8Q51132568-06859477-3D4E-4177-90F7-4A785005CA14Q53514928-F05250B6-BEBD-46D1-B869-B30FDFD08133Q57779831-40CD427D-3FFA-4273-97D3-C183BD938841
P2860
Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Identification of somatostatin ...... ent of human endocrine tumors.
@en
type
label
Identification of somatostatin ...... ent of human endocrine tumors.
@en
prefLabel
Identification of somatostatin ...... ent of human endocrine tumors.
@en
P2093
P2860
P356
P1476
Identification of somatostatin ...... ent of human endocrine tumors.
@en
P2093
Kagimoto S
Shimatsu A
P2860
P304
P356
10.1172/JCI117090
P407
P577
1994-03-01T00:00:00Z